ISRCTN14881793
Active, Not Recruiting
N/A
Evaluating the effectiveness of the Nuffield Early Language Intervention using a regression discontinuity design
Education Endowment Foundation0 sites350 target enrollmentSeptember 17, 2020
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- anguage disorder
- Sponsor
- Education Endowment Foundation
- Enrollment
- 350
- Status
- Active, Not Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Children must be in Reception class
- •2\. Children must be aged 4 to 5 years at pretest
- •3\. Children receiving the NELI\-R programme will be selected for having language weaknesses in comparison to their peers at school entry
Exclusion Criteria
- •1\. Children with such severe sensory impairments that they are unable to access the language screening assessment
- •2\. Children with such severe emotional or behavioural issues that they are unable to access the language screening assessment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
An evaluation of the effectiveness of the Nuffield Early Language Intervention (NELI) programme in New ZealandDevelopmental language difficultiesMental and Behavioural DisordersISRCTN15660056niversity of Canterbury432
Not Yet Recruiting
N/A
Effect of Implementing the Early Movement Protocol on the amount of Postoperative BleedingIRCT20231120060120N2Zahedan University of Medical Sciences46
Completed
N/A
The Effectiveness of the First phase of Cardiac Rehabilitation on the Frequency of Readmission and Quality of LifeCoronary Artery Bypass Surgery.IRCT20171223038015N2Karaj University of Medical Sciences100
Not Yet Recruiting
N/A
The effect of graduated return to high-intensity exercise on time to return to play in the context of sports-related concussions.Sports-related concussionMild Traumatic Brain InjuryACTRN12618000485235Dr Hamish Osborne50
Active, Not Recruiting
Phase 1
Study to evaluate the efficacy of obinutuzumab in mantle cell lymphoma patients treated by DHAPMantle Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-000548-33-FRYSARC